Aquestive Therapeutics (NASDAQ: AQST)
$3.08
(-4.2%)
-$0.14
Price as of January 8, 2025, 12:50 p.m. ET
Aquestive Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aquestive Therapeutics Company Info
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
News & Analysis
Featured Article
Why Aquestive Therapeutics Dived by 29% Today
A decision on a crucial regulatory filing is being delayed indefinitely.
Eric Volkman | Dec 21, 2021
Featured Article
These 2 Pharma Stocks Could Be Top Stocks in 2020
These pharma stocks are undervalued, and could be solid picks over the long term.
Amar Khatri | Jul 6, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.